In a new study from the William Osler Health Centre, researchers found for people with mild-to-moderate COVID-19 and a high risk for progression, sotrovimab could help reduce the risk for hospitalization or death.
They assigned patients with mild-to-moderate COVID-19 and at least one risk factor for progression to either sotrovimab or placebo (528 and 529 patients, respectively).
The researchers found a strong reduction in hospitalization lasting longer than 24 hours or death through day 29 with sotrovimab versus placebo.
Four of the five secondary outcomes were strongly in favor of sotrovimab, including decreased emergency department visits, hospitalizations, or deaths and reduced progression to severe or critical respiratory COVID-19.
Adverse events occurred infrequently and were similar between the groups (22 and 23 percent for sotrovimab and placebo, respectively).
The findings support sotrovimab as a treatment option for nonhospitalized, high-risk patients with mild-to-moderate COVID-19.
Although efficacy against severe acute respiratory syndrome coronavirus 2 variants that have emerged since the study was completed is unknown.
If you care about COVID, please read studies about existing drug that could inhibit COVID-19 virus, and findings that aspirin and other common anti-inflammatory drugs could help prevent COVID-19 deaths.
For more information about COVID, please see recent studies that CBD from cannabis may inhibit COVID-19 infection, and results showing why people with blood Type O less likely to get COVID-19.
The study is published in the Journal of the American Medical Association and was conducted by Anil Gupta et al.
Copyright © 2022 Knowridge Science Report. All rights reserved.